August 24, 2016 11:05 PM ET


Company Overview of CellProthera SAS

Company Overview

CellProthera SAS operates as a medical biotechnology company in France. It focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing autologous adult stem cells sampled directly from the patient. The company was founded in 2008 and is based in Mulhouse, France.

40, Rue Marc Seguin


Mulhouse,  68060


Founded in 2008


33 3 89 64 74 18

Key Executives for CellProthera SAS

Chief Executive Officer and Ad Interim Chief Marketing Officer
Chief Operating Officer
Chairman, Chief Scientific Officer and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2016.

CellProthera SAS Key Developments

CellProThera and BioCardia Sign Agreement to Partner on the EXCELLENT Trial

CellProThera and BioCardia announced an agreement to partner on the EXCELLENT (Expanded Cell Endocardiac Transplantation) Trial, controlled Phase I/IIb study to evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand(R) Automated Process and delivered via the BioCardia Helix(TM) Transendocardial Delivery System. The agreement calls for payments to BioCardia, which are creditable to a future clinical development program, and payments to CellProThera for timely completion of the Phase II study. The trial will study patients with an acute myocardial infarction (AMI) and a left ventricle ejection fraction (LVEF) remaining below or equal to 45% after percutaneous transluminal coronary angioplasty (PTCA) and stent(s) implantation versus standard of care. The study will encompass 44 patients treated at up to eight centers in the United Kingdom and France and followed for six months. Co-principal investigators are Jerome Roncalli, MD, PhD, Department of Cardiology, University Hospital of Toulouse, France, and David E. Newby, MD, PhD, University Centre for Cardiovascular Science of Edinburgh, Scotland. The primary endpoint of the study is no treatment emergent major adverse cardiac events (MACE) at 30 days post-procedure. Secondary endpoints will assess the first efficacy trends, the viability of the infarcted segments, safety of the Helix transendocardial delivery procedure and quality of life. In order to simplify and standardize the cell graft production process, CellProThera developed an Automated Process using a cell expansion automate StemXpand(R) and disposable kit StemPack(R). This enables GMP production of as many stem cells as those obtained with one leukapheresis, starting from a whole autologous blood sample simply drawn after G-CSF mobilization, thus avoiding leukapheresis sessions. In pre-clinical studies, the expanded CD34+ cells (Protheracytes(R)) have demonstrated the same therapeutic efficacy as naive cells with no chromosomic alteration, toxicity or tumorogenicity. The Helix Transendocardial Delivery System is a steerable, two-catheter system that enables delivery of biologic therapies to the heart muscle from within the chamber of the heart. The system's unique performance advantages include crossing the aortic valve over a wire to prevent damage; enhanced navigation using the company's steerable Morph(R) guiding catheter; a helical needle which screws into the myocardium for stable delivery; and the use of contrast at the base of the needle to confirm tissue engagement.

Similar Private Companies By Industry

Company Name Region
Acticor Biotech S.A.S. Europe
Ademtech SA Europe
Aelis Farma S.A.S. Europe
Aenitis Technologies SAS Europe
Alderys SAS Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CellProthera SAS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at